Open AccessFeasibility of cabazitaxel in octogenarian prostate cancer patients
Author(s) -
Paolo Tralongo,
Sebastiano Bordonaro,
Giuseppe Di Lorenzo,
Ugo De Giorgi,
Nicolò Borsellino,
Gaetano Facchini,
Sabrina Rossetti,
Giuseppe Fornarini,
Vito Longo,
Antonino Carmelo Tralongo,
F Caspani,
Massimiliano Spada,
Nicola Calvani,
Paolo Carlini
Publication year - 2022
Publication title -
current urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.476
H-Index - 13
eISSN - 1661-7657
pISSN - 1661-7649
DOI - 10.1097/cu9.0000000000000081
Subject(s) - medicine , cabazitaxel , prostate cancer , cancer , oncology , androgen deprivation therapy
To evaluate the effectiveness and safety of cabazitaxel in castration-resistant prostate cancer patients aged ≥80 years, we performed a retrospective study on a sample of patients from 11 Italian cancer centers.